Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Keros Therapeutics, Inc.KROS · Entity 6242 | Director · 10% owner | April 13, 2020 | April 13, 2020 |
| Werewolf Therapeutics, Inc.HOWL · Entity 7244 | Director | June 12, 2025 | June 13, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Keros Therapeutics, Inc.
Report date April 13, 2020 · Filed April 13, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,013,102 |
Last balance in matching sequence
After 2020-04-13 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2020-04-13 · Conversion · Acquired 1,382,295 · Balance 1,382,295 F1: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. The Reporting Person, a member of the board of directors of the Issuer, is the Biotech Investment Manager of the Pharma Division of Arkin Holdings, and, as a result, may be deemed to share voting and investment power with respect to the shares held by Arkin Bio. The Reporting Person disclaims beneficial ownership of the shares held by Arkin Bio, except to the extent of his pecuniary interest therein. Row 2 · 2020-04-13 · Conversion · Acquired 343,270 · Balance 1,725,565 F1: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. The Reporting Person, a member of the board of directors of the Issuer, is the Biotech Investment Manager of the Pharma Division of Arkin Holdings, and, as a result, may be deemed to share voting and investment power with respect to the shares held by Arkin Bio. The Reporting Person disclaims beneficial ownership of the shares held by Arkin Bio, except to the extent of his pecuniary interest therein. Row 3 · 2020-04-13 · Conversion · Acquired 167,537 · Balance 1,893,102 F1: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. The Reporting Person, a member of the board of directors of the Issuer, is the Biotech Investment Manager of the Pharma Division of Arkin Holdings, and, as a result, may be deemed to share voting and investment power with respect to the shares held by Arkin Bio. The Reporting Person disclaims beneficial ownership of the shares held by Arkin Bio, except to the extent of his pecuniary interest therein. Row 4 · 2020-04-13 · Purchase · Acquired 120,000 · Balance 2,013,102 F2: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. The Reporting Person, a member of the board of directors of the Issuer, is the Biotech Investment Manager of the Pharma Division of Arkin Holdings, and, as a result, may be deemed to share voting and investment power with respect to the shares held by Arkin Bio. The Reporting Person disclaims beneficial ownership of the shares held by Arkin Bio, except to the extent of his pecuniary interest therein. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-04-13 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-04-13 · Conversion · Disposed 1,382,295 · Balance 0 F1: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. The Reporting Person, a member of the board of directors of the Issuer, is the Biotech Investment Manager of the Pharma Division of Arkin Holdings, and, as a result, may be deemed to share voting and investment power with respect to the shares held by Arkin Bio. The Reporting Person disclaims beneficial ownership of the shares held by Arkin Bio, except to the extent of his pecuniary interest therein. |
| Series B-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-04-13 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-04-13 · Conversion · Disposed 343,270 · Balance 0 F1: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. The Reporting Person, a member of the board of directors of the Issuer, is the Biotech Investment Manager of the Pharma Division of Arkin Holdings, and, as a result, may be deemed to share voting and investment power with respect to the shares held by Arkin Bio. The Reporting Person disclaims beneficial ownership of the shares held by Arkin Bio, except to the extent of his pecuniary interest therein. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-04-13 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-04-13 · Conversion · Disposed 167,537 · Balance 0 F1: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. The Reporting Person, a member of the board of directors of the Issuer, is the Biotech Investment Manager of the Pharma Division of Arkin Holdings, and, as a result, may be deemed to share voting and investment power with respect to the shares held by Arkin Bio. The Reporting Person disclaims beneficial ownership of the shares held by Arkin Bio, except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 23,038 |
Reported balance
Holding disclosure · report date 2020-04-13 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 23,038 |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.
F2: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. The Reporting Person, a member of the board of directors of the Issuer, is the Biotech Investment Manager of the Pharma Division of Arkin Holdings, and, as a result, may be deemed to share voting and investment power with respect to the shares held by Arkin Bio. The Reporting Person disclaims beneficial ownership of the shares held by Arkin Bio, except to the extent of his pecuniary interest therein.
Werewolf Therapeutics, Inc.
Report date June 12, 2025 · Filed June 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.29 · Expires 2035-06-11 | Direct | 27,000 |
Reported balance
After 2025-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-12 · Grant · Acquired 27,000 · Balance 27,000 F1: The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2025 Filed Jun 13, 2025 16:10 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0000950170-25-086174 · ownership.xml · derivative · entry 1 Lazarus Alon · CIK 0001808244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2035-06-11 F1 · derivative.exercise_date: The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director. Read SEC document |
| May 24, 2024 Filed May 24, 2024 19:44 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $4.88 | $0.00 |
DisclosureSEC source: 0000950170-24-064829 · ownership.xml · derivative · entry 1 Lazarus Alon · CIK 0001808244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2034-05-23 F1 · derivative.exercise_date: The option was granted on May 24, 2024. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 16:52 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 13,200 | $0.00 Strike: $2.81 | $0.00 |
DisclosureSEC source: 0000899243-23-016380 · doc4.xml · derivative · entry 1 Lazarus Alon · CIK 0001808244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,200 Underlying: Common Stock · 13,200 shares Expires 2033-06-20 F1 · derivative.exercise_date: The option was granted on June 21, 2023. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 16:39 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 11,600 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0000899243-22-020982 · doc4.xml · derivative · entry 1 Lazarus Alon · CIK 0001808244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,600 Underlying: Common Stock · 11,600 shares Expires 2032-05-31 F1 · derivative.exercise_date: The option was granted on June 1, 2022. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director. Read SEC document |
| May 04, 2021 Filed May 4, 2021 16:30 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | ConversionSeries B Preferred Stock · Derivative | 3,560,551 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-018111 · doc4.xml · derivative · entry 7 Lazarus Alon · CIK 0001808244 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 410,717 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · derivative.exercise_date: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · derivative.expiration_date: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The securities are held directly by Arkin Bio Ventures 2 L.P. (the "Fund"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. The Reporting Person is the Biotech Investment Manager of the Fund and, as a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd., Mr. Arkin and the Reporting Person may be deemed to share voting and investment power with respect to the shares held by the Fund. Read SEC document |
| May 04, 2021 Filed May 4, 2021 16:30 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | ConversionSeries A Preferred Stock · Derivative | 10,714,284 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-018111 · doc4.xml · derivative · entry 6 Lazarus Alon · CIK 0001808244 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,235,917 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The securities are held directly by Arkin Bio Ventures 2 L.P. (the "Fund"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. The Reporting Person is the Biotech Investment Manager of the Fund and, as a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd., Mr. Arkin and the Reporting Person may be deemed to share voting and investment power with respect to the shares held by the Fund. Read SEC document |
| May 04, 2021 Filed May 4, 2021 16:30 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | PurchaseCommon Stock | 400,000 | $16.00 | $6,400,000.00 |
DisclosureSEC source: 0000899243-21-018111 · doc4.xml · nonDerivative · entry 3 Lazarus Alon · CIK 0001808244 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,046,634 F2 · ownership.nature: The securities are held directly by Arkin Bio Ventures 2 L.P. (the "Fund"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. The Reporting Person is the Biotech Investment Manager of the Fund and, as a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd., Mr. Arkin and the Reporting Person may be deemed to share voting and investment power with respect to the shares held by the Fund. Read SEC document |
| May 04, 2021 Filed May 4, 2021 16:30 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | ConversionCommon Stock | 410,717 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-018111 · doc4.xml · nonDerivative · entry 2 Lazarus Alon · CIK 0001808244 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,646,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The securities are held directly by Arkin Bio Ventures 2 L.P. (the "Fund"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. The Reporting Person is the Biotech Investment Manager of the Fund and, as a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd., Mr. Arkin and the Reporting Person may be deemed to share voting and investment power with respect to the shares held by the Fund. Read SEC document |
| May 04, 2021 Filed May 4, 2021 16:30 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | ConversionCommon Stock | 1,235,917 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-018111 · doc4.xml · nonDerivative · entry 1 Lazarus Alon · CIK 0001808244 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,235,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The securities are held directly by Arkin Bio Ventures 2 L.P. (the "Fund"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. The Reporting Person is the Biotech Investment Manager of the Fund and, as a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd., Mr. Arkin and the Reporting Person may be deemed to share voting and investment power with respect to the shares held by the Fund. Read SEC document |
| April 30, 2021 Filed May 4, 2021 16:30 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 23,200 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-21-018111 · doc4.xml · derivative · entry 5 Lazarus Alon · CIK 0001808244 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,200 Underlying: Common Stock · 23,200 shares Expires 2031-04-29 F5 · derivative.exercise_date: The option was granted on April 30, 2021. The shares underlying the option vest over three years, with one-third of the shares vesting on the first anniversary of the date of grant and the remaining shares vesting in equal monthly installments thereafter. Read SEC document |
| December 23, 2020 Filed May 4, 2021 16:30 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | PurchaseSeries B Preferred Stock · Derivative | 3,560,551 | $0.92 | $3,280,691.69 |
DisclosureSEC source: 0000899243-21-018111 · doc4.xml · derivative · entry 4 Lazarus Alon · CIK 0001808244 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,560,551 Underlying: Common Stock · 410,717 shares Expires not disclosed F4 · derivative.exercise_price: The Series B Preferred Stock was convertible into common stock on a 8.6691-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4 · derivative.exercise_date: The Series B Preferred Stock was convertible into common stock on a 8.6691-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4 · derivative.expiration_date: The Series B Preferred Stock was convertible into common stock on a 8.6691-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The securities are held directly by Arkin Bio Ventures 2 L.P. (the "Fund"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. The Reporting Person is the Biotech Investment Manager of the Fund and, as a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd., Mr. Arkin and the Reporting Person may be deemed to share voting and investment power with respect to the shares held by the Fund. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 17:15 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionSeries C Preferred Stock · Derivative | 167,537 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024228 · doc4.xml · derivative · entry 8 Lazarus Alon · CIK 0001808244 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 167,537 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2 · ownership.nature: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. The Reporting Person, a member of the board of directors of the Issuer, is the Biotech Investment Manager of the Pharma Division of Arkin Holdings, and, as a result, may be deemed to share voting and investment power with respect to the shares held by Arkin Bio. The Reporting Person disclaims beneficial ownership of the shares held by Arkin Bio, except to the extent of his pecuniary interest therein. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 17:15 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionSeries B-1 Preferred Stock · Derivative | 343,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024228 · doc4.xml · derivative · entry 7 Lazarus Alon · CIK 0001808244 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 343,270 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2 · ownership.nature: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. The Reporting Person, a member of the board of directors of the Issuer, is the Biotech Investment Manager of the Pharma Division of Arkin Holdings, and, as a result, may be deemed to share voting and investment power with respect to the shares held by Arkin Bio. The Reporting Person disclaims beneficial ownership of the shares held by Arkin Bio, except to the extent of his pecuniary interest therein. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 17:15 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionSeries A Preferred Stock · Derivative | 1,382,295 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024228 · doc4.xml · derivative · entry 6 Lazarus Alon · CIK 0001808244 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,382,295 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2 · ownership.nature: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. The Reporting Person, a member of the board of directors of the Issuer, is the Biotech Investment Manager of the Pharma Division of Arkin Holdings, and, as a result, may be deemed to share voting and investment power with respect to the shares held by Arkin Bio. The Reporting Person disclaims beneficial ownership of the shares held by Arkin Bio, except to the extent of his pecuniary interest therein. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 17:15 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | PurchaseCommon Stock | 120,000 | $16.00 | $1,920,000.00 |
DisclosureSEC source: 0001209191-20-024228 · doc4.xml · nonDerivative · entry 4 Lazarus Alon · CIK 0001808244 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,013,102 F2 · ownership.nature: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. The Reporting Person, a member of the board of directors of the Issuer, is the Biotech Investment Manager of the Pharma Division of Arkin Holdings, and, as a result, may be deemed to share voting and investment power with respect to the shares held by Arkin Bio. The Reporting Person disclaims beneficial ownership of the shares held by Arkin Bio, except to the extent of his pecuniary interest therein. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 17:15 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionCommon Stock | 167,537 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-024228 · doc4.xml · nonDerivative · entry 3 Lazarus Alon · CIK 0001808244 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,893,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2 · ownership.nature: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. The Reporting Person, a member of the board of directors of the Issuer, is the Biotech Investment Manager of the Pharma Division of Arkin Holdings, and, as a result, may be deemed to share voting and investment power with respect to the shares held by Arkin Bio. The Reporting Person disclaims beneficial ownership of the shares held by Arkin Bio, except to the extent of his pecuniary interest therein. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 17:15 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionCommon Stock | 343,270 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-024228 · doc4.xml · nonDerivative · entry 2 Lazarus Alon · CIK 0001808244 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,725,565 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2 · ownership.nature: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. The Reporting Person, a member of the board of directors of the Issuer, is the Biotech Investment Manager of the Pharma Division of Arkin Holdings, and, as a result, may be deemed to share voting and investment power with respect to the shares held by Arkin Bio. The Reporting Person disclaims beneficial ownership of the shares held by Arkin Bio, except to the extent of his pecuniary interest therein. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 17:15 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionCommon Stock | 1,382,295 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-024228 · doc4.xml · nonDerivative · entry 1 Lazarus Alon · CIK 0001808244 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,382,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2 · ownership.nature: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. The Reporting Person, a member of the board of directors of the Issuer, is the Biotech Investment Manager of the Pharma Division of Arkin Holdings, and, as a result, may be deemed to share voting and investment power with respect to the shares held by Arkin Bio. The Reporting Person disclaims beneficial ownership of the shares held by Arkin Bio, except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.